Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
4.280
-0.080 (-1.83%)
At close: Sep 11, 2026, 4:00 PM EDT
4.250
-0.030 (-0.70%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
63
Market Cap
348.68M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
| Dec 31, 2021 | 1.66M | 1.14M | 219.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Orchestra BioMed Holdings | 31.98M |
| Zentalis Pharmaceuticals | 26.87M |
| X4 Pharmaceuticals | 15.85M |
| Ocugen | 4.58M |
| EyePoint | 2.79M |
| Compass Therapeutics | 850.00K |
| Palisade Bio | 500.00K |
LXEO News
- 4 days ago - Lexeo Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 11 days ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 27 days ago - Lexeo Therapeutics reports Q2 EPS (30c), consensus (28c) - TheFly
- 4 weeks ago - Lexeo Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights - GlobeNewsWire
- 4 weeks ago - Lexeo Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Lexeo Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Lexeo Therapeutics management to meet with Cantor - TheFly